Summary 'Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights, 2014', report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the ... Individual.com, 1 month ago
Normalization of Low-Density Lipoprotein Receptor Expression inReceptor Defective Homozygous Familial Hypercholesterolemia byInhibition of PCSK9 With Alirocumab - Journal of the American College of Cardiology, 2 months ago
FDA gives PCSK9 inhibitor priority review - Cardiovascular Business, 5 days ago
2 images for "kexin"
John-Henry Krueger won the men's 1,000-meter race and China's Fan Kexin dominated the women's competition at the Apolo Ohno Invitational on Friday night. Krueger was the only American to win an event, beating Canada's Charles Hamelin and China's ...Miami Herald, 2 months ago
It was the final day of competition from the latest stop on the Short Track Speed Skating circuit. And China was looking to add to their medal haul from the opening day, when they grabbed two gold medals in Seoul. In the women's 3000m relay, team ...CNTV, 1 month ago Fan spearheads China in short track World Cup China.org.cn, 1 month ago XINHUA - Fan spearheads China in short track World Cup Namibia Press Agency, 1 month ago
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.1 "The long-term ...Individual.com, 2 months ago Amgen reports encouraging data from Phase II and III high cholesterol analyses Individual.com, 2 months ago Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab 4 Traders, 2 months ago AMGEN PRESENTS LONG-TERM DATA OF INVESTIGATIONAL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB ACROSS LIPID AND LDL-C LEVELS Noodls, 2 months ago
Research and Markets ( http://www.researchandmarkets.com/research/swbspq/china_paraquat ) has announced the addition of the "China Paraquat Export Overview" report to their offering. China paraquat product export overlook provides ...Town Hall, 1 day ago China Paraquat Export Overview Report 2014-2015 Individual.com, 21 hours ago Global Slitter Industry and PIN Diode Market 2014 Research Reports Stock Nod, 1 month ago Global PIN Diode Industry Report 2014-2020 Individual.com, 1 month ago
More from: Town Hall, Avid...and 53 other sources
Treatment for High Cholesterol Paris and Tarrytown, New York January 26, 2015 Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License ...Drugs.com, 22 hours ago Hypercholesterolemia Treatment Granted FDA Priority Review Pharmacy Times, 4 days ago Sanofi and Regeneron's Praluent BLA gains priority review from US FDA26-01-2015 Pharma Letter, 4 days ago Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Trials Evaluating Monthly Alirocumab Drugs.com, 4 days ago
Regeneron Pharmaceuticals : Details Findings in Immunoglobulins (Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in...
Regeneron Pharmaceuticals Inc. Details Findings in Immunoglobulins (Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial) By a ...4 Traders, 1 week ago
Preamble This overview of key studies, published in 2014, regarding epidemiology and prevention of cardiovascular disease (CVD) illustrates the great potential of CVD prevention as summarized in recent guidelines. New insights became available in ...European Heart Journal, 1 week ago
The American Heart Association's annual scientific session in Chicago offered insights on the latest therapies and practices, from statin treatments and screening tools to readmissions and communications. Here is a roundup of presentations from the ...Cardiovascular Business, 1 week ago
In this inaugural installment of guest posts from clinicians at the Cleveland Clinic, Steven E. Nissen, MD , explains why he sees 2015 as a momentous year for cardiology. During the last decade, pharmaceutical companies have introduced very few ...MedPage Today, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!